Explore Medicare changes in 2026, including $50 GLP-1 weight-loss drug coverage, Medicare Advantage prior authorization denials, and the 2027 outlook.
Medicare is experiencing another wave of important changes in 2026, affecting prescription drug coverage, healthcare access, and Medicare Advantage insurance plans. These developments are particularly important for older Americans who depend on Medicare to manage their healthcare expenses and access medical services.
One of the biggest developments is the introduction of Medicare Part B coverage for certain GLP-1 weight-loss medications at a monthly price of $50. At the same time, a new government study has raised concerns about Medicare Advantage insurance companies denying requests for hospital-level and rehabilitation care.
Meanwhile, Medicare Advantage insurers are beginning to recover from several financially challenging years. Lower-than-expected medical care demand and more favorable government reimbursement rates are improving their financial outlook.
These developments could influence healthcare decisions for millions of Medicare beneficiaries across the United States.
Here are the three major Medicare changes and developments that Americans should understand.
1. Medicare Introduces $50 Monthly Coverage for GLP-1 Weight-Loss Drugs
One of the most significant Medicare changes in 2026 involves coverage for GLP-1 medications prescribed for weight loss.
Beginning July 1, Medicare started covering qualifying GLP-1 prescriptions for weight loss under Part B at a cost of $50 per month.
Previously, Medicare was prohibited from covering these medications when prescribed solely for weight loss. However, the medications were already covered under Part D when prescribed for diabetes.
The new coverage represents an important development for beneficiaries who may have wanted to use these medications but found them financially difficult to afford.
According to the Forbes report by Bob Carlson, the new benefit is a temporary program scheduled to continue through December 31, 2027.
Why Could GLP-1 Coverage Increase Demand?
The introduction of lower-cost coverage could encourage more eligible Medicare beneficiaries to seek GLP-1 medications.
Analysts expect that many individuals who could benefit from these drugs have not previously been able to afford them.
As a result, the new coverage could generate significant additional demand.
However, increased demand could also create challenges for medication availability. Analysts have raised concerns that greater demand might lead to supply shortages.
This means that while the new benefit could improve affordability for qualifying beneficiaries, medication availability could become another issue to watch.
Prior Authorization Requirements for GLP-1 Medications
The new Medicare benefit is not automatically available to everyone.
Beneficiaries must go through a prior authorization process to determine whether they meet the requirements for the lower-cost prescriptions.
Some healthcare professionals have also expressed concerns about whether patients will receive sufficient counseling.
Proper medication use involves understanding dosage requirements, making adjustments when necessary, and knowing how to manage potential side effects.
Therefore, access to affordable medication is only one part of the overall healthcare process.
2. Medicare Advantage Faces Concerns Over Prior Authorization Denials
Another important Medicare development involves prior authorization decisions made by Medicare Advantage insurance plans.
A study by the Office of the Inspector General of the Department of Health and Human Services examined how Medicare Advantage plans handled requests for hospital-level and rehabilitation care.
The findings raised concerns about differences in denial rates among insurance providers.
According to the study, the three largest Medicare Advantage plans denied requests for inpatient rehabilitation facilities and long-term care hospitals at higher rates than 16 other Medicare Advantage plans.
The research used a sample of data from June 2024.
What Did the Medicare Advantage Study Find?
The study identified two particularly important findings:
- The three largest Medicare Advantage plans denied almost two-thirds of requests for hospital-level care.
- More than half of requests for admission to rehabilitation facilities were also denied.
These denial rates were higher than those recorded among the other 16 Medicare Advantage plans examined in the study.
However, another important finding was that many denied requests were subsequently reversed after beneficiaries appealed the decisions.
This highlights the importance of understanding how prior authorization works within Medicare Advantage coverage.
For beneficiaries, the findings raise questions about access to necessary hospital and rehabilitation services.
For insurance providers, they highlight the importance of reviewing authorization procedures and ensuring that coverage decisions are handled appropriately.
3. Medicare Advantage Insurance Companies Are Recovering Financially
While coverage and authorization issues remain important, another major development concerns the financial condition of Medicare Advantage insurers.
Many insurance companies experienced significant financial pressure over the previous few years.
Several factors contributed to these difficulties, including higher medical care demand, inflation, and changes in government reimbursement policies.
Higher Healthcare Costs Created Financial Pressure
During the pandemic, many individuals delayed or neglected medical treatment.
Over the following three years, Medicare Advantage members returned to healthcare providers to receive care they had previously postponed.
As a result, medical care demand exceeded insurers’ expectations.
Insurance companies had established their premiums and coverage arrangements based on lower expected healthcare costs.
When actual medical expenses increased, many insurers found themselves spending significantly more than anticipated.
Inflation, which began in 2021, also increased the costs of different types of medical care.
Together, these developments placed additional pressure on Medicare Advantage insurance companies.
Government Reimbursement Changes Affected Insurers
Another challenge involved changes in government reimbursement policies.
The government determined that Medicare Advantage insurers had been receiving more generous payments than appropriate.
Consequently, reimbursement rates were set lower than many insurance companies had expected.
Additional government policy changes also eliminated certain practices that Medicare Advantage plans had previously used to increase reimbursements.
These developments contributed to sharply reduced profits and, in some cases, financial losses.
Some insurers decided to leave the Medicare Advantage market.
Others responded by offering fewer plans and increasing premiums, deductibles, and copayments.
Certain plans also reduced coverage, particularly for additional benefits that are not included in Original Medicare.
4. Why the Medicare Advantage Market Could Become More Stable in 2027
Despite the financial challenges of recent years, the latest earnings reports from most Medicare Advantage insurers indicate improving conditions.
According to the Forbes analysis, medical care demand has not increased as significantly as it did during the previous few years.
Insurers are reporting lower healthcare costs than they originally expected.
Government reimbursement rates have also been more favorable in 2026 compared with the previous couple of years. They are also expected to remain more favorable in 2027.
These developments have contributed to improved earnings reports and stock prices over the last year.
As a result, the Medicare Advantage insurance market could become more stable in 2027.
However, the actual situation will become clearer when the annual open enrollment period begins in October.
5. What Medicare Beneficiaries Should Watch
The latest developments demonstrate that Medicare is not a completely static healthcare program.
Changes in prescription coverage, prior authorization procedures, healthcare costs, and insurance company finances can influence the experience of beneficiaries.
The new GLP-1 coverage introduces an opportunity for qualifying individuals to access weight-loss medications at a lower monthly price.
At the same time, the prior authorization study highlights concerns about access to hospital-level and rehabilitation services under Medicare Advantage.
Finally, improving insurer financial conditions could help create a more stable Medicare Advantage market in 2027.
Beneficiaries should pay attention to official coverage requirements and understand how their individual plans handle prescription medications and medical service requests.
Conclusion: Medicare Changes in 2026 Bring New Opportunities and Challenges
The latest Medicare developments represent an important period of change for American healthcare beneficiaries.
The introduction of $50 monthly GLP-1 weight-loss drug coverage under Part B is a major development in prescription affordability, although prior authorization and potential supply shortages remain concerns.
Meanwhile, the findings about Medicare Advantage prior authorization denials highlight the importance of healthcare access and appeal procedures.
On the financial side, Medicare Advantage insurers are showing signs of recovery after several difficult years of higher medical costs, inflation, and reimbursement changes.
Looking ahead, 2027 could bring a more stable Medicare Advantage market, although the actual outcome will become clearer during the next open enrollment period.
For American seniors and other Medicare beneficiaries, staying informed about these changes is essential to understanding their healthcare coverage and making informed decisions.
Source: Bob Carlson, Forbes, July 13, 2026.
Disclaimer: This article is for informational and educational purposes only. Medicare coverage eligibility and individual costs depend on applicable program requirements and plan terms. Readers should consult official Medicare information and their healthcare providers for personal decisions.